The goal of the CHAPAS-5 clinical trial is to find out how well different HIV treatments work in children and young people (from 4 weeks up to under 15 years old) living with HIV, including those starting treatment for the first time and those whose current treatment is not working well.
The study aims to learn whether newer or different combinations of medicines can better control the virus, be safer, and be easier to take.
The main questions it aims to answer are:
* Can these treatments help children stay alive and keep their HIV virus at very low levels (viral load below 400) after 48 weeks?
* Which treatment options are most effective, safest, and easiest for children and their carers to use?
Researchers will compare different treatment groups to see if some medicines work better than others. Participants will be given one of several HIV treatment combinations (all already used in care), and these will be compared to see if they lead to:
* Better control of HIV
* Fewer side effects
* Improved quality of life
Participants will:
* Be randomly assigned (like flipping a coin by computer) to one suitable HIV treatment
* Take their HIV medication every day as prescribed
* Attend clinic visits over about 1-2 years
At these visits, they will:
* Have blood tests to check HIV levels and general health
* Have health check-ups (e.g. weight, symptoms, side effects)
* Answer simple questionnaires about:
* How easy the treatment is to take
* Mood, sleep, and wellbeing
* Quality of life
* Receive support to help them take their medication regularly
Some participants may also take part in optional extra studies (for example, to understand how the drugs work in the body).
Overall, this study aims to identify the best HIV treatments for children and young people, so future care can be more effective, safer, and easier to follow.

Start Date01 Nov 2026

Sponsor / Collaborator

University College London

[+7]

NCT07124559

/ Not yet recruitingPhase 1/2IIT

Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

This study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB). The study will take place at multiple locations and children under 13 years old will be divided into two groups: one group will include children without HIV, and the other group will include children with HIV who are on antiretroviral treatment. Up to 144 children will participate, and participants in each group will be followed for 24 weeks.

Start Date15 Oct 2026

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

[+1]

NCT05652478

/ RecruitingPhase 2IIT

Early Metabolic Effects of Antiretroviral Drugs in Healthy Volunteers: A Phase 2 Randomized Study

Background:
People with HIV take drugs to keep the amount of virus in their body low. One type of these drugs, called integrase strand transfer inhibitors (INSTIs), can cause weight gain over time. Weight gain can cause diabetes, heart disease, and other serious issues. Researchers want to understand how INSTIs cause weight changes.
Objective:
To characterize the change in plasma metabolite profile that 4 weeks of each treatment may induce in the absence of HIV infection
Eligibility:
Healthy people aged 18 to 55.
Design:
Participants will be screened in the outpatient clinic. They will have a physical exam and blood tests. They will have a nutritional assessment and tests of their heart function.
Participants will be randomized to one of four oral treatments: Tenofovir Disoproxil Fumarate TDF, Tenovovir Alafenamide TAF/Vemlidy, Dolutegravir DTG/Tivicay, or both TAF and DTG taken together for 4 weeks.
Participants will have a Day 0 visit for the Lead-In Baseline visit for an exam and blood tests and continuous glucose monitor placement.
Participants will return in 2wks or Day 14/Wk 2 for a DEXA (dual-energy X-ray absorptiometry). DEXA is a kind of X-ray that measures body fat and bone density. Optional adiopse (fat) tissue biopsy in the abdomen, and optional microbiome specimen collections. Continuous glucose monitor changed. Oral once a day dose medication will be started with education.
Participants will return in 2wks or Day 28/Wk 4 for exam, labs, and continuous glucose monitor changed.
Participants will return in 2wks or Day 42/Wk 6 for final exam, labs, repeat DEXA scan, repeat adipose tissue biopsy, and microbiome specimen collections.

Start Date09 Sep 2026

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

100 Clinical Results associated with Dolutegravir Sodium

100 Translational Medicine associated with Dolutegravir Sodium

100 Patents (Medical) associated with Dolutegravir Sodium

3,524

Literatures (Medical) associated with Dolutegravir Sodium

31 Dec 2026·ANNALS OF MEDICINE

Efficacy and metabolic outcomes of switching from an INSTI-based triple-drug regimen to dolutegravir/lamivudine in treatment-experienced HIV-1-infected patients: a 48-week real-world study

Article

Author: Li, Qisui ; Zhang, Wei ; Yuan, Jing ; Deng, Changgang

BACKGROUND:

Real-world data on switching from INSTI-based triple therapy to DTG/3TC in the Chinese population are lacking.

METHODS:

This retrospective study included 214 treatment-experienced patients with HIV from Chongqing Public Health Medical Center (2021-2022) on an INSTI-based triple-drug regimen for ≥6 months who switched to DTG/3TC for >12 months. Patients with pre-existing metabolic diseases were excluded. Participants were categorized: INSTI+TAF-free (n = 100, prior TDF/AZT/ABC), INSTI+TAF (n = 56, prior BIC/FTC/TAF), and INSTI+TAF+COBI (n = 58, prior EVG/c/FTC/TAF). Virological, immunological, and metabolic parameters were assessed at weeks 24 and 48.

RESULTS:

The INSTI+TAF+COBI group was significantly older (p=0.000). Virological suppression rates (<50 copies/mL) were high at switch (93%, 85.7%, 91.4%). The INSTI+TAF+COBI group had lower eGFR and higher TG, TC, HDL, and LDL at baseline (p < 0.05). After switching, virological suppression remained high (≥90%) at weeks 24 and 48. CD4+ T-cell increases showed no significant intergroup differences. Metabolic changes differed: TC changes were 0.57 mmol/L (IQR: -0.19-0.91) in INSTI+TAF-free, -0.09 mmol/L (-0.47-0.71) in INSTI+TAF, and -0.25 mmol/L (-0.99-0.33) in INSTI+TAF+COBI. LDL changes were 0.23 mmol/L (-0.23-0.67), -0.15 mmol/L (-0.39-0.01), and -0.18 mmol/L (-0.71-0.10), respectively. TC and LDL changes differed significantly among groups (p < 0.05).

CONCLUSION:

Switching to DTG/3TC maintained virological suppression and stable immunological outcomes. Patients previously on TAF-containing regimens demonstrated greater metabolic benefits than those on TAF-free regimens, possibly related to baseline TDF effects, requiring further confirmation.

31 Dec 2026·ASN Neuro

Exposure to Frontline Antiretroviral Dolutegravir Disrupts Oligodendrocyte Development Across Differentiation Stages

Article

Author: Cruz-Berríos, Melanie ; Grinspan, Judith B. ; Putatunda, Raj ; Romer, Micah A. ; Jeffries, Marisa A. ; Jordan-Sciutto, Kelly L. ; Singhal, Anushka

The use of antiretroviral (ART) treatment during pregnancy has dramatically reduced rates of perinatally-acquired human immunodeficiency virus 1 (HIV-1) infection to <1% in the United States. Despite this success, we have limited knowledge of how ART drugs that cross the placental barrier affect fetal development, particularly in the central nervous system (CNS). During gestation, large populations of oligodendroglia are produced that are responsible for critical postnatal CNS myelination enabling appropriate neurological function. Previous studies have shown that antiretrovirals impair oligodendrocyte (OL) differentiation leading us to hypothesize that OL maturation might be inhibited by exposure to a frontline ART drug cocktail (Triumeq®) prescribed during pregnancy containing dolutegravir (DTG), abacavir (ABC), and lamivudine (3TC). In this study, we demonstrated that exposing primary rat oligodendrocyte precursor cells (OPCs) and OLs to the Triumeq drug combination decreased OL maturation and myelin protein production in a concentration-dependent manner, and that DTG was solely responsible. Regardless of the timing of exposure during OL development, a high concentration of DTG inhibited OL maturation. Bulk RNA sequencing revealed transcriptional changes after DTG exposure related to a variety of cellular mechanisms, including cellular responses to stress pathways, amino acid starvation, and mitochondrial dysfunction. Although we found that DTG robustly activated the integrated stress response (ISR), attempted rescue experiments showed that DTG primarily inhibits OL maturation independently of the ISR. Collectively, our novel data on DTG underscore the necessity of investigating how ART drugs that are administered during pregnancy and cross the placental barrier can affect fetal CNS development.

31 Dec 2026·HIV Research & Clinical Practice

Longitudinal analysis of viral suppression before, during, and after pregnancy among women on antiretroviral therapy in Uganda: six-year real-world experience

Article

Author: Mumbere, Iving ; Emunyu, Jude ; Sserunjogi, Conrad ; Namasambi, Sharon ; Kyomuhangi, Brendah ; Nakawesi, Jane ; Ankunda, Collins

INTRODUCTION:

This study evaluated the effectiveness of antiretroviral therapy (ART) and associated factors on viral suppression before, during, and after pregnancy (maternal timeline).

METHODS:

We conducted a cohort study, retrospectively reviewing records of 1291 pregnant and breastfeeding women on ART. Descriptive statistics summarised the demographics and clinical characteristics. Chi-square, Fisher's exact, and generalised estimating equations were used to assess variations in viral suppression across the maternal timeline.

RESULTS:

ART regimens comprised 62.5% dolutegravir (DTG)-, 28.8% efavirenz (EFV)-, 4.5% nevirapine (NVP)-, and 4.2% protease inhibitor (PI)-based therapy. Viral suppression rates before, during, and after pregnancy were DTG- (95.0%, 94.6%, 95.7%), EFV- (94.9%, 94.2%, 93.6%), NVP- (93.1%, 94.7%, 93.5%), and PI-based (79.6%, 88.0%, 85.7%). ART regimens varied in effectiveness, with statistical significance observed before (p < 0.001) and after (p = 0.018), but not during pregnancy (p = 0.678). PI-based regimens showed higher risk of non-suppression in the non-adjusted model (IRR = 3.20, 95% CI: 1.63-6.30, p = 0.001). In the adjusted model, poor adherence (aIRR = 7.80, 95% CI: 2.54-23.90, p < 0.001), fair adherence (aIRR = 5.03, 95% CI: 1.11-22.86, p = 0.036), second-line ART (aIRR = 3.14, 95% CI: 1.75-5.62, p < 0.001), and third-line ART (aIRR = 8.48, 95% CI: 1.82-39.43, p = 0.006) remained significant.

CONCLUSION:

ART effectiveness showed variation before and after, but not during pregnancy. EFV- and NVP-based regimens achieved suppression rates comparable to DTG across maternal timelines, with the exception of PI-based regimens. Adherence and ART drugs influence outcomes more than regimen choice alone, with good adherence essential for optimal maternal outcomes.

185

News (Medical) associated with Dolutegravir Sodium

28 Aug 2026

·allsci.com

FDA approves Gilead's Bixlenvo to simplify complex HIV regimens

The US FDA has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single-tablet regimen (STR) for HIV-1 treatment in virologically suppressed adults — including, for the first time, those on complex multi-tablet regimens who could not previously use an STR. Gilead Sciences (Nasdaq: GILD) said the combination is the smallest oral STR and the first approved STR option for virologically suppressed patients on complex regimens who are unable to use existing STRs because of factors including historical resistance or tolerability. Bixlenvo is indicated as a complete regimen for adults with HIV-1 RNA below 50 copies per mL on a stable antiretroviral regimen, with no known or suspected resistance to either component. Initiation requires a two-day loading period with Sunlenca (lenacapavir) co-administered alongside Bixlenvo, after which Bixlenvo is taken alone once daily. Contraindications include co-administration with dofetilide and strong CYP3A inducers. Approval rested on two Phase III trials — ARTISTRY-1 (NCT05502341) and ARTISTRY-2 (NCT06333808) — both evaluating virologic suppression maintenance at Week 48 after switching to Bixlenvo. ARTISTRY-1 enrolled a notably treatment-experienced population: median age 60 years, median 28 years on antiretroviral therapy, 67% with nucleoside reverse transcriptase inhibitor (NRTI) resistance, and 81% on complex regimens due to resistance. Both trials reported comparable efficacy to prior regimens and no new safety signals; the most common adverse reactions were headache (4%), nausea (3%), and diarrhea (2%). ARTISTRY-1 results were published in The Lancet and ARTISTRY-2 in Lancet HIV. Bictegravir is an integrase strand transfer inhibitor (INSTI) that blocks insertion of viral cDNA into the host genome. Lenacapavir, a first-in-class capsid inhibitor also marketed as Sunlenca, disrupts capsid-dependent processes across multiple stages of the HIV lifecycle — nuclear import, uncoating, and virion assembly — with no cross-resistance to other approved antiretroviral classes. The approval adds another option to an increasingly competitive HIV switch market that includes ViiV Healthcare's Dovato (dolutegravir/lamivudine), long-acting injectable Cabenuva (cabotegravir/rilpivirine), and Merck's recently approved Idvynso (doravirine/islatravir). Bixlenvo is differentiated by its ability to simplify treatment for some heavily treatment-experienced patients currently requiring complex multi-tablet regimens. Spot something wrong? Report an issue with this article

Phase 3Drug ApprovalClinical ResultClinical StudyOligonucleotide

27 Aug 2026

·www.pharmaceutical-technology.com

ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy

The studies indicated that dolutegravir reached therapeutic levels in neonates and showed a safety profile similar to older patients. Credit: Gorodenkoff/Shutterstock.com. The US Food and Drug Administration (FDA) has approved ViiV Healthcare’s Tivicay PD (dolutegravir), for use with other antiretroviral agents in paediatric patients with human immunodeficiency virus type 1 (HIV-1) who weigh at least 2kg. The therapy is indicated for children who are either new to treatment or have prior experience with antiretroviral therapies but have not been treated with integrase strand transfer inhibitors (INSTIs). ViiV Healthcare is a global HIV specialist company, majority owned by GSK, with Shionogi as a shareholder. Tivicay PD’s approval follows a Priority Review by the FDA. The decision is backed by data from the International Maternal Paediatric Adolescent AIDS Clinical Trials (IMPAACT) 2023 clinical study, funded by the National Institutes of Health (NIH), as well as additional paediatric pharmacokinetic modelling. The studies indicated that dolutegravir, described as a second-generation INSTI, reached therapeutic levels in term neonates and demonstrated a safety profile similar to that of older children and adults taking the drug. ViiV Healthcare chief medical officer Jean van Wyk said: “Today’s approval of Tivicay PD expands the options available for paediatric HIV care, giving families and clinicians in the US greater choice from the very beginning of life. “For ViiV Healthcare, it reflects our commitment to bringing INSTI-based innovation to children and addressing persistent gaps in HIV care. “This progress has been made possible through vital collaboration with the HIV community, united by a shared focus on ensuring children living with HIV are not left behind.” Tivicay and Tivicay PD both contain dolutegravir, which is designed to inhibit HIV integrase and block a critical step in the virus’ replication cycle. IMPAACT, the clinical research network behind the pivotal trial, brings together investigators and partners worldwide. It studies interventions for HIV and related conditions across different populations. The NIH, which supported the research, is the primary US federal agency for medical investigation and part of the Department of Health and Human Services. In February 2025, the European Commission authorised the use of ViiV Healthcare’s Vocabria (cabotegravir long-acting injections) plus Rekambys (rilpivirine long-acting injections) from Johnson & Johnson for treating adolescents with HIV-1.

Drug ApprovalClinical StudyPriority Review

26 Aug 2026

·www.businesswire.com

U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir (DTG)), for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in paediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor (INSTI)-naïve) weighing at least 2 kg. Diana F. Clarke, Pharm.D., Assistant Professor of Paediatrics, Boston University School of Medicine and Lead Investigator of the IMPAACT 2023 study, said: “For too long, newborns living with HIV have had too few treatment options designed and studied to meet their unique needs, despite the importance of starting treatment as early as possible. With the approval of a Tivicay PD dosing regimen, babies born at term and weighing at least 2 kg will now have access to dolutegravir-based therapy starting at birth. This represents an important advance for the care of newborns, as early treatment with the most effective therapies results in the best possible outcomes.” Without early diagnosis and treatment, HIV can progress rapidly in infants, with around 50% of untreated infants with HIV dying by age two.1 The urgent need for effective treatment options underscores the importance of broadening access to modern, age-appropriate HIV medicines for this vulnerable group, and this expanded indication builds on ViiV Healthcare's broader efforts to provide HIV treatment options across the paediatric treatment journey. Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said: “Today’s approval of Tivicay PD expands the options available for paediatric HIV care, giving families and clinicians in the U.S. greater choice from the very beginning of life. For ViiV Healthcare, it reflects our commitment to bringing INSTI-based innovation to children and addressing persistent gaps in HIV care. This progress has been made possible through vital collaboration with the HIV community, united by a shared focus on ensuring children living with HIV are not left behind.” The FDA approval follows Priority Review for this population and is supported by data from the National Institutes of Health (NIH)-funded IMPAACT 2023 study and pharmacokinetic (PK) modelling incorporating additional paediatric data. These data showed that DTG, a second-generation INSTI with a higher barrier to resistance than previous generations, reached therapeutic drug levels in term neonates with a safety profile consistent with that established in older paediatric and adult populations. About Tivicay and Tivicay PD Tivicay and Tivicay PD contain dolutegravir, an INSTI for use in combination with other antiretroviral agents for the treatment of HIV. Integrase inhibitors inhibit HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Please consult the full Prescribing Information here. Trademarks are owned by or licensed to the ViiV Healthcare group of companies. About IMPAACT The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is a global collaboration of investigators, institutions, community representatives, and other partners with a mission to improve health outcomes in infancy, childhood, adolescence, pregnancy, and postpartum among those who are impacted by or living with HIV, tuberculosis, and other related complications through the conduct of high-quality clinical trials. IMPAACT’s vision and overall goal is to end the worldwide HIV epidemic among these populations. To achieve this goal, the IMPAACT Network evaluates novel and durable treatments for HIV, TB, and related diseases and conditions, strategies for antiretroviral treatment (ART)-free remission, and strategies to prevent and manage neuropsychological and mental health complications of HIV and its treatment. Overall support and funding for IMPAACT is provided by the National Institute of Allergy and Infectious Diseases (NIAID), with support and co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), all components of the United States National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. For more information, please visit: www.impaactnetwork.org. About the National Institutes of Health (NIH) NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit: www.nih.gov. About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 with GSK (LSE: GSK) and Shionogi as current shareholders. The company is dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. ViiV Healthcare’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025, and GSK’s Q2 Results for 2026. Registered in England & Wales: GSK plc ViiV Healthcare Limited No. 3888792 No. 06876960 Registered Office: 79 New Oxford Street ViiV Healthcare Limited London GSK Medicines Research Centre WC1A 1DG Gunnels Wood Road, Stevenage United Kingdom SG1 2NY References _________________ 1 UNICEF and UNAIDS. The Cost of Inaction: Children and Adolescents Living with HIV in Eastern and Southern Africa. Available at: https://www.childrenandaids.org/media/6096/file/UNICEF_UNAIDS_CostofInaction_HIV_Final.pdf. Last accessed August 2026.

Drug ApprovalClinical StudyPriority Review

100 Deals associated with Dolutegravir Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D10113	Dolutegravir Sodium	J05AX12	DB08930

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	ViiV Healthcare Co.	12 Aug 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pregnancy	Phase 3	South Africa	ViiV Healthcare Ltd.	14 Mar 2017
Pregnancy	Phase 3	Uganda	ViiV Healthcare Ltd.	14 Mar 2017
Pulmonary Tuberculosis	Phase 3	Argentina	GSK Plc	23 Jan 2015
Pulmonary Tuberculosis	Phase 3	Brazil	ViiV Healthcare Ltd.	23 Jan 2015
Pulmonary Tuberculosis	Phase 3	Mexico	GSK Plc	23 Jan 2015
Pulmonary Tuberculosis	Phase 3	Peru	GSK Plc	23 Jan 2015
Pulmonary Tuberculosis	Phase 3	Russia	GSK Plc	23 Jan 2015
Pulmonary Tuberculosis	Phase 3	South Africa	GSK Plc	23 Jan 2015
Pulmonary Tuberculosis	Phase 3	Thailand	GSK Plc	23 Jan 2015
Tuberculosis	Phase 3	Argentina	GSK Plc	23 Jan 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IAS2026	Not Applicable	HIV Infections	1,214	Dolutegravir	fqcgrhwyww(fnfqnteuru) = tolhwukbfz evmoygbwfg (kqzxmxxpwr ) View more	Positive	26 Jul 2026
CODE (IAS2026)	Not Applicable	HIV Infections	4,525	ART-naïve initiating DTG	jhixhauipo(qiwnvcjtqa) = brokbvomim kfuxagqjka (ztmiojzrot ) View more	Positive	26 Jul 2026
				DolutegravirDTG (suppressed clients switching to DTG)	jhixhauipo(qiwnvcjtqa) = zlcygthatc kfuxagqjka (ztmiojzrot ) View more
IAS2026	Not Applicable	HIV Infections	4,988	Dolutegravir-based ART	fcphbnczit(yznmmkbpqd) = gzgkmisjbi slrbagrazp (pqqnfvdhmd ) View more	Positive	26 Jul 2026
				started non-DTG ART	fcphbnczit(yznmmkbpqd) = muondvvxro slrbagrazp (pqqnfvdhmd ) View more
NCT04734652 (INSIGHT, IAS2026)	Phase 2	Tuberculosis	42	tenofovir-lamivudine-dolutegravir 300/300/50mg (HIV + tuberculosis)	rsqcqqgxph(vqqvnwpkbc) = nzfftixjoq nkdgkmakkh (lmdhzgnlav ) View more	Positive	26 Jul 2026
NCT04746547 (ORCHID, IAS2026)	Phase 4	HIV Infections	16	Dolutegravir	wryznitezb(ilprzkoazg) = ahbnrtwgtx rynkmrdpeq (xdwxtzlzpt, 162 - 1330) View more	Positive	26 Jul 2026
IAS2026	Not Applicable	HIV Infections	166	dolutegravir (starting pDTG)	nuczubfpqv(rqceqiwsgz) = wtqpsvcxoc zhwndywfei (ipesqyokxz ) View more	Positive	26 Jul 2026
				dolutegravir (switching to pDTG)	nuczubfpqv(rqceqiwsgz) = dthmwnjnoc zhwndywfei (ipesqyokxz ) View more
IAS2026	Not Applicable	HIV Infections	239,027	dolutegravir (Extended Multi-month Dispensing (MMD) cohort)	ewhsrrmomb(bvlyjvgxnu) = zgzayfpnyc ynwpdnkjcy (zrenvtetbs ) View more	Positive	26 Jul 2026
				dolutegravir (Biennial Viral Load (VL) monitoring cohort)	tspdxpvsqn(nqgtdkowdt) = xczynswjoz ulqxynpoba (oqxrpnxkve, 97.9 - 98.4)
IAS2026	Not Applicable	HIV Infections	1,114	dolutegravir-based ART	pvcylpfevu(seduieoaec) = bsbxgtksbe ywsksifhwf (vvmcktptxn ) View more	Positive	26 Jul 2026
IAS2026	Not Applicable	HIV Infections	4,092	Dolutegravir-based regimens (TLD)	dprkzvcsxy(pabsiwdvjv) = mswbdbmvtn lrsuobpfhr (atbbdhnfwr ) View more	Positive	26 Jul 2026
				Dolutegravir-based regimens (TLD) (died)	oycmyljyiq(erkjqtsjqv) = wltvzmwifm plkocmxlgu (hfhqfavzlv ) View more
NCT05630872 (CTgov)	Phase 2	Tuberculosis \| Pulmonary Tuberculosis	30	TDF/3TC+Dolutegravir+rifapentine+moxifloxacin+isoniazid+pyrazinamide	segehczmuw = shpzxnselo ciqmpmmzss (dktswfqkmw, jaowpbymmj - xuzjubsbkb) View more	-	20 Jul 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis